About Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Market Cap
$0.10B
Employees
14
Listed Since
September 4, 2002
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.galectintherapeutics.comPhone
678-620-3186
Headquarters
4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
CIK
0001133416